Synonym: 5-[[[(3-Phenoxyphenyl)methyl][(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl]-1,2,4-benzenetricarboxylic acid sodium salt hydrate
Empirical Formula (Hill Notation): C33H27NO8 · xNa+ · yH2O
Molecular Weight: 565.57 (anhydrous free acid basis)
Linear Formula: C33H27NO8 · xNa+ · yH2O
Product Type: Chemical
| assay |
≥98% (HPLC) |
| color |
white to beige |
| form |
powder |
| InChI |
1S/C33H27NO8.Na.H2O.H/c35-30(25-17-27(32(38)39)28(33(40)41)18-26(25)31(36)37)34(29-15-7-10-21-9-4-5-14-24(21)29)19-20-8-6-13-23(16-20)42-22-11-2-1-3-12-22;;;/h1-6,8-9,11-14,16-18,29H,7,10,15,19H2,(H,36,37)(H,38,39)(H,40,41);;1H2;/t29-;;;/m0.../s1 |
| InChI key |
VEMCGHRDAPMXLI-VYEUTZPBSA-N |
| originator |
Abbott |
| Quality Level |
100  |
| SMILES string |
[Na].[H]O[H].OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc2cccc(Oc3ccccc3)c2)[C@H]4CCCc5ccccc45 |
| solubility |
H2O: 15 mg/mL, clear |
| Application: |
A-317491 sodium salt hydrate has been used to block the P2X3 receptor. It has also been used to block the increased membrane conductance. |
| Biochem/physiol Actions: |
A-317491 helps to decrease neuropathic and inflammatory pain by inhibiting the P2X3 receptor-mediated Ca2+ influx. |
| Biochem/physiol Actions: |
Novel P2X3 and P2X2/3 receptor antagonist |
| Features and Benefits: |
This compound is featured on the P2 Receptors: P2X Ion Channel Family page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: |
This compound was developed by Abbott . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Legal Information: |
Subject to U.S. Patent No. 6,831,193. Sold under license from Abbott Laboratories |
| Packaging: |
5, 25 mg in glass bottle |
| RIDADR |
NONH for all modes of transport |
| WGK Germany |
WGK 3 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
| Purity |
≥98% (HPLC) |
| UNSPSC |
12352200 |
